Physician profile
Julie E Thomas
NPI 1700179207
$1,858.07
in general payments reported to CMS, 2019-2025
22 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $344 · 2023: $490 · 2024: $141 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $269.38 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $243.48 | 2021-2025 | |
| Genzyme Corporation | $216.38 | 2021-2025 | |
| Leo Pharma INC. | $194.06 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $128.54 | 2023-2025 | |
| Almirall LLC | $82.61 | 2021-2025 | Klisyri |
| Janssen Biotech, INC. | $74.34 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Arcutis Biotherapeutics, INC. | $74.32 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $73.71 | 2022-2025 | |
| Amgen INC. | $61.51 | 2022-2023 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.32 | 2025 | Cabtreo |
| Novartis Pharmaceuticals Corporation | $57.09 | 2022-2025 | |
| Galderma Laboratories, L.P. | $53.81 | 2021-2025 | Nemluvio, Epsolay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.24 | 2023 | Spevigo |
| Lilly USA, LLC | $49.81 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $39.79 | 2023-2025 | Sotyktu |
| Botanix Sb INC | $24.83 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $24.73 | 2024 | Ycanth |
| Dermavant Sciences, INC. | $24.09 | 2024 | Vtama |
| Incyte Corporation | $20.87 | 2025 | Opzelura |
| Pfizer INC. | $17.16 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.